Company Filing History:
2 out of 12,164 
1 out of 1,537 
Years Active: 2025
Title: Innovations by Andreas Wilmen
Introduction
Andreas Wilmen is a notable inventor based in Cologne, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies. With a total of three patents to his name, his work focuses on enhancing therapeutic methods through advanced antibody engineering.
Latest Patents
Wilmen's latest patents include groundbreaking inventions related to antibodies that incorporate heterologous amino acid sequences. One of his notable patents is for "Brain natriuretic peptide engrafted antibodies." This invention describes an antibody or a fragment that includes a heterologous amino acid sequence within its CDR regions, specifically featuring a Brain Natriuretic Peptide (BNP). The patent outlines the potential applications of this antibody in treatment methods, as well as the processes for producing it.
Another significant patent is for "Atrial natriuretic peptide engrafted antibodies." Similar to his previous work, this invention involves an antibody that incorporates an Atrial Natriuretic Peptide (ANP) within its structure. The patent details the use of this antibody in therapeutic applications and the methods for its production.
Career Highlights
Throughout his career, Andreas Wilmen has worked with prominent companies in the pharmaceutical industry. He has been associated with Bayer Aktiengesellschaft and Boehringer Ingelheim International GmbH, where he has contributed to various research and development projects. His expertise in antibody engineering has positioned him as a valuable asset in these organizations.
Collaborations
Wilmen has collaborated with several professionals in his field, including Ernst Weber and Damian Brockschnieder. These collaborations have likely enriched his research and contributed to the success of his innovative projects.
Conclusion
Andreas Wilmen's contributions to biotechnology through his patented inventions demonstrate his commitment to advancing medical treatments. His work in antibody engineering continues to pave the way for new therapeutic possibilities.